L2 DIAGNOSTICS LLC
- NEW HAVEN, CT 06525-1231
- l2dx.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $899.5K
- Awards on record
- 2
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
L2 DIAGNOSTICS LLC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About L2 DIAGNOSTICS LLC
- Headquarters
- NEW HAVEN, CT 06525-1231
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIGKA7VH5LFR25
- CAGE43BA5
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
- 36-month obligations
- $899.5K
- Awards on record
- 2
- Top funding agencies
- National Institutes of Health
Awards
75N93025C00024
Recompete 6–12 mo: Potential end Jul 31, 2027 (8 months away)THERAPEUTIC VACCINE PLATFORM TO BOOST IMMUNE RESPONSES IN TUBERCULOSIS
Department of Health and Human Services · National Institutes of Health
- Obligated
- $599.5K
- Period of performance
- Aug 1, 2025 – Jul 31, 2027
75N93025C00004
Completed: Period of performance ended Nov 30, 2025NOVEL DIAGNOSTIC BIOMARKERS DISCOVERY AND VALIDATION FOR MALARIA SBIR PHASE I
Department of Health and Human Services · National Institutes of Health
- Obligated
- $300K
- Period of performance
- Dec 1, 2024 – Nov 30, 2025
| Award | Agency | NAICS · PSC | Obligated | Period of performance | Recompete |
|---|---|---|---|---|---|
75N93025C00024 THERAPEUTIC VACCINE PLATFORM TO BOOST IMMUNE RESPONSES IN TUBERCULOSIS | Department of Health and Human Services · National Institutes of Health | 541715 · AN11HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH | $599.5K | Aug 1, 2025 – Jul 31, 2027 | Recompete 6–12 mo: Potential end Jul 31, 2027 (8 months away)AI brief for award 75N93025C00024Bid team for the recompete of award 75N93025C00024 |
75N93025C00004 NOVEL DIAGNOSTIC BIOMARKERS DISCOVERY AND VALIDATION FOR MALARIA SBIR PHASE I | Department of Health and Human Services · National Institutes of Health | 541714 · AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH | $300K | Dec 1, 2024 – Nov 30, 2025 | Completed: Period of performance ended Nov 30, 2025 |
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 96 awards
- Total awarded
- $50,841,483
- By phase
- SBIR Phase I: 41
- STTR Phase I: 36
- SBIR Phase II: 12
- STTR Phase II: 7
- By agency
- Department of Health and Human Services: 94
- Department of Defense: 2
- Active projects
- 4 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2025: 6
- 2024: 4
- 2022: 1
- 2021: 1
- 2020: 3
- 2019: 4
- 2018: 4
- 2017: 4
- 2016: 3
- 2015: 2
- 2014: 7
- 2013: 2
- 2012: 5
- 2011: 4
- 2010: 3
- 2009: 2
- 2008: 6
- 2007: 1
- 2006: 7
- 2005: 4
- 2004: 9
- 2003: 6
- 2002: 2
- 2001: 2
- 2000: 2
- 1999: 2
Awards (most recent first)
A viral vector-based vaccine to induce humoral and cellular immune protection against Powassan virus in a tick transmission model
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $281,786
Sep 23, 2025 – Aug 31, 2027
- Active
Solicitation PA24-247 (2024) · Topic NIAID · Research partner: YALE UNIVERSITY
A vaccine targeting mosquito metabolic pathways to eradicate malaria
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $299,644
Sep 23, 2025 – Aug 31, 2027
- Active
Solicitation PA24-247 (2024) · Topic NIAID · Research partner: YALE UNIVERSITY
A Point of Care Test for Babesia microti
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $293,142
Sep 21, 2025 – Aug 31, 2027
- Active
Solicitation PA23-230 (2023) · Topic NIAID
PfAg, a multivalent peptide vaccine against malaria
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $299,954
Sep 15, 2025 – Aug 31, 2027
- Active
Solicitation PA24-247 (2024) · Topic NIAID · Research partner: YALE UNIVERSITY
Novel Diagnostic Biomarker Discovery and Validation for Malaria
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $300,000
Solicitation PHS 2024-1 (2023) · Topic 132
THERAPEUTIC VACCINE PLATFORM TO BOOST IMMUNE RESPONSES IN TUBERCULOSIS
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $599,471
Solicitation PHS 2025-1 (2025) · Topic 137
The mosquito salivary protein AgBR1 as vaccine candidate against Chikungunya
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $599,938
Jul 17, 2024 – Jun 30, 2026
Solicitation PA23-232 (2023) · Topic NIAID · Research partner: YALE UNIVERSITY
A novel therapeutic for Lyme arthritis based on a secretory leukocyte protease inhibitor
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $599,866
Jul 8, 2024 – Jun 30, 2026
Solicitation PA23-232 (2023) · Topic NIAID · Research partner: YALE UNIVERSITY
Delivery of a candidate AgTRIOVx malaria vaccine by thermostable microneedle patches
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $599,740
Jun 1, 2024 – May 31, 2026
Solicitation PA23-232 (2023) · Topic NIAID · Research partner: YALE UNIVERSITY
A Multivalent mRNA Vaccine to Prevent Transmission of Tick-bornePathogens
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $597,612
May 1, 2024 – Apr 30, 2026
Solicitation PA23-232 (2023) · Topic NIAID · Research partner: YALE UNIVERSITY
A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $2,948,061
Aug 18, 2022 – Jul 31, 2025
Solicitation PA20-265 (2020) · Topic NIAID · Research partner: YALE UNIVERSITY
A therapeutic for Lyme disease based on Peptidoglycan Recognition Protein 1
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $599,028
Aug 4, 2021 – Jul 31, 2023
Solicitation PA20-265 (2020) · Topic NIAID · Research partner: YALE UNIVERSITY
An antigen-detection assay to diagnose Babesia microti infection
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $2,076,246
Jun 22, 2020 – May 31, 2023
Solicitation PA19-272 (2019) · Topic NIAID
Vaccination against Zika virus infection using mosquito NeSt1 protein
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $593,086
Jun 16, 2020 – May 31, 2022
Solicitation PA19-270 (2019) · Topic NIAID · Research partner: YALE UNIVERSITY
Multiplexed Bioassay for Checkpoint Inhibitor Autoimmunity
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $298,911
Dec 9, 2019 – Nov 30, 2021
Solicitation PA18-575 (2018) · Topic NIAID · Research partner: YALE UNIVERSITY
Targets of Acquired Tick-Resistance As Anti-Tick Vaccines
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $596,625
Jul 1, 2019 – Jun 30, 2021
Solicitation PA18-575 (2018) · Topic NIAID · Research partner: YALE UNIVERSITY
Development of A Narrow Spectrum Anti-Tubercular Agent
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $585,337
Jul 1, 2019 – Jun 30, 2021
Solicitation PA18-574 (2018) · Topic NIAID
Immunization with mosquito AgTRIO protein to prevent malaria
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $592,338
Apr 16, 2019 – Mar 31, 2021
Solicitation PA18-575 (2018) · Topic NIAID · Research partner: YALE UNIVERSITY
A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $594,226
Jan 21, 2019 – Dec 31, 2020
Solicitation PA18-575 (2018) · Topic NIAID · Research partner: YALE UNIVERSITY
Therapeutic Inhibition of BCL6 in Systemic Lupus Erythematosus
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $225,000
Sep 11, 2018 – Aug 31, 2019
Solicitation PA17-303 (2017) · Topic NIAMS · Research partner: RUTGERS THE STATE UNIV OF NJ NEWARK
Development of a Point of Care Diagnostic Screening test for Kawasaki disease
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $224,963
Aug 11, 2018 – Jul 31, 2019
Solicitation PA17-303 (2017) · Topic NICHD · Research partner: YALE UNIVERSITY
Therapeutic Inhibition of MIF to Improve Glucocorticoid Response
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $453,442
Feb 8, 2018 – Jul 31, 2020
Solicitation PA17-302 (2017) · Topic NIAID
An antigen-detection assay to diagnose Babesia microti infection
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $299,975
Jan 10, 2018 – Dec 31, 2019
Solicitation PA16-302 (2016) · Topic NIAID
Novel diagnostics for autoimmunity from checkpoint inhibitor immune therapy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $299,754
Sep 15, 2017 – Aug 31, 2019
Solicitation PA16-302 (2016) · Topic NIDDK
Validation of a Diagnostic Test for Borrelia miyamotoi
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $574,217
Aug 14, 2017 – Jul 31, 2019
Solicitation PA16-303 (2016) · Topic NIAID · Research partner: UNIV OF MASSACHUSETTS MED SCH WORCESTER
Showing the 25 most recent of 96 awards.
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)Primary
- 621511Medical Laboratories
SAM.gov does not report this entity as small under any listed NAICS code.
Socio-economic status
No socio-economic certifications reported in SAM.gov.
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with L2 DIAGNOSTICS LLC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.